CXCL2 Protein

Catalog No. ABIN7455624

Recombinant CXCL2 protein expressed in Escherichia coli (E. coli).

Quick Overview for CXCL2 Protein (ABIN7455624)

Target: CXCL2 (Chemokine (C-X-C Motif) Ligand 2 (CXCL2))

Protein Type: Recombinant

Origin: Human

Source: Escherichia coli (E. coli)

Purity: Greater than 95 % as determined by reducing SDS-PAGE.

Product Details

Purpose: Recombinant Human C-X-C Motif Chemokine 2 is produced by our E.coli expression system and the target gene encoding Thr39-Asn107 is expressed.

Characteristics: Extracellular Domain Protein

Purification: Affinity purification

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Lyophilized from a 0.2 μm filtered solution of 20 mM Tris-HCl, 150 mM NaCl, pH 8.0.

Storage: -20 °C,-80 °C

Storage Comment: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Expiry Date: 12 months

Target Details

Target: CXCL2 (Chemokine (C-X-C Motif) Ligand 2 (CXCL2))

Alternative Name: CXCL2

Background: Chemokine Ligand 2 (CXCL2) is a small secreted cytokine which belongs to the CXC chemokine family. It is secreted by monocytes and macrophages and chemotactic for polymorphonuclear leukocytes and hematopoietic stem cells. CXCL2 mobilizes cells by interacting with a cell surface chemokine receptor called CXCR2. It has been known to regulate immune functions mainly by chemo-attracting neutrophils. It is produced by activated monocytes and neutrophils and expressed at sites of inflammation. It is a hematoregulatory chemokine, which suppresses hematopoietic progenitor cell proliferation. It can be induced by receptor activator of NF-kappaB ligand, the osteoclast (OC) differentiation factor, through JNK and NF-kappaB signaling pathways in OC precursor cells. CXCL2 in turn enhanced the proliferation of OC precursor cells of bone marrow-derived macrophages (BMMs) through the activation of ERK. Knockdown of CXCL2 inhibited both the proliferation of and the ERK activation in BMMs. During osteoclastogenesis CXCL2 stimulated the adhesion and the migration of BMMs. CXCL2 is a novel therapeutic target for inflammatory bone destructive diseases.

Molecular Weight: 7.67 KDa

UniProt: P19875

Pathways: Cellular Response to Molecule of Bacterial Origin